Last reviewed 2026-04-23 · How we verify

F520

F520 is a small molecule that targets the SGLT2 receptor.

F520 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Mechanism of action

F520 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.

Approved indications

• Type 2 diabetes

Common side effects

• Nausea
• Diarrhea
• Vomiting

Key clinical trials

• A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma (PHASE2)
• A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
• Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors (PHASE1, PHASE2)
• A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL (PHASE2)
• A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma (PHASE2)
• The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). (PHASE2)
• Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520 (PHASE1)
• A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• F520 CI brief — competitive landscape report
• F520 updates RSS · CI watch RSS
• Shandong New Time Pharmaceutical Co., LTD portfolio CI